NEW YORK (GenomeWeb) – Rubicon Genomics today announced it has secured $2 million in growth capital financing.
BroadOak Capital Partners led the round, joined by Research Corporation Technologies.
The Ann Arbor, Michigan-based sample prep firm said it will use the proceeds to develop new and existing products, including its ThruPlex Plasma-seq liquid biopsy kit, and to add to its sales and marketing. Among the firm's other products are the ThruPLEX DNA-seq, PicoPLEX DNA-seq, and PicoPLEX WGA Kits.
"This investment reflects our view that Rubicon is an important player in one of the fastest growing markets in life sciences–next-generation sequencing," BroadOak Managing Partner Bill Snider said in a statement.